Business
Medicenna Provides Positive Interim Update From Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
Medicenna Provides Positive Interim Update From Phase 2b Trial of MDNA55 in Recurrent Glio...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Provides Positive Interim Update From Phase 2b Trial of MDNA55 in Recurrent Glioblastoma\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen5{\nBORDER-TOP:black 1pt solid; BORDER-RIGHT:black 1pt solid; BORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: CENTER; PADDING-LEFT:0.50em; BORDER-LEFT:black 1pt solid; PADDING-RIGHT:1.17em\n}\n.prngen4{\nBORDER-TOP:black 1pt solid; BORDER-RIGHT:black 1pt solid; BORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 1pt solid; PADDING-RIGHT:0.50em\n}\n.prngen3{\nBORDER-TOP:black 1pt solid; BORDER-RIGHT:black 1pt solid; BORDER-BOTTOM:black 1pt solid; TEXT-ALIGN: CENTER; PADDING-LEFT:0.50em; BORDER-LEFT:black 1pt solid; PADDING-RIGHT:0.50em\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prntbls{\nBORDER-TOP: black 1px solid; BORDER-RIGHT: black 1px solid; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbtb0{\nBORDER-TOP:black 0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, Oct. 31, 2018\n\n\n\nPromising signs of clinical benefit and survival observed at low doses of MDNA55\n TORONTO and HOUSTON, TX, Oct. 31, 2018 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA and OTCQB: MDNAF) a clinical stage immuno-oncology company, today announced promising interim efficacy and safety results from patients treated at low doses in the on-going Phase 2b clinical trial of MDNA55 in recurrent glioblastoma (\"rGBM\"), the most common and uniformly fatal form of brain cancer.\nThe open-label study, funded in part by a non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT), is designed to evaluate the efficacy and safety of MDNA55 in approximately 52 adults with rGBM at 1st or 2nd relaps...